Online inquiry

IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14030MR)

This product GTTS-WQ14030MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14030MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5044MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ12159MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ8217MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ14092MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ14142MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ4063MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ13246MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13314MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW